Yueqiong (Bernard) Ni

Dr. Yueqiong (Bernard) Ni

Microbiome Dynamics +49 3641 532-1268 yueqiong.ni@leibniz-hki.de


Chen J*, Leal Siliceo S*, Ni Y, Nielsen HB, Xu A, Panagiotou G (2023) Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions. Microbiome 11(1), 178.
Leung H, Xiong L, Ni Y, Busch A, Bauer M, Press AT, Panagiotou G (2023) Impaired flux of bile acids from the liver to the gut reveals microbiome-immune interactions associated with liver damage. NPJ Biofilms and microbiomes 9(1), 35.
Mirhakkak MH*, Chen X*, Heinekamp T, Sae-Ong T, Xu LL, Ni Y, Kurzai O, Barber AE, Brakhage AA, Boutin S, Schäuble S#, Panagiotou G# (2023) Genome-scale Metabolic modeling of Aspergillus fumigatus strains reveals growth dependencies on the lung microbiome. Nat Commun 14(1), 4369.
Ni Y*, Qian L*, Leal Siliceo S*, Long X*, Nychas E, Liu Y, Ismaiah MJ, Leung H, Zhang L, Gao Q, Wu Q, Zhang Y, Jia Xi, Liu S, Yuan R, Zhou L, Wang X, Li Q, Zhao Y, El-Nezami H, Xu A, Xu G#, Li H#, Panagiotou G#, Jia W# (2023) Resistant starch decreases intrahepatic triglycerides in NAFLD patients via gut microbiome alterations. Cell Metabolism 35, 1530-1547.
Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H, Jia W, Panagiotou G (2022) Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med 14(648), eabk0855.
Kang K, Imamovic L, Misiakou M, Sørensen MB, Heshiki Y, Ni Y, Zheng T, Li J, Ellabaan MMH, Colomer-Lluch M, Rode AA, Bytzer P, Panagiotou G#, Sommer MOA (corresponding author#) (2021) Expansion and persistence of antibiotic-specific resistance genes following antibiotic treatment. Gut Microbes 13(1), 1-19.
Marfil-Sanchez A*, Seelbinder B *, Ni Y, Varga J, Berta J, Hollosi V, Dome B, Megyesfalvi Z, Dulka E, Galffy G, Weiss GJ, Panagiotou G#, Zoltan Lohinai Z# (2021) Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients. PLOS One 16(11), e0259898.
Marfil-Sánchez A*, Zhang L*, Alonso-Pernas P, Mirhakkak M, Mueller M, Seelbinder B, Ni Y, Santhanam R, Busch A, Beemelmanns C, Ermolaeva M, Bauer M#, Panagiotou G# (2021) An integrative understanding of the large metabolic shifts induced by antibiotics in critical illness. Gut Microbes 13(1), 1993598.
Mirhakkak M, Schäuble S, Klassert T, Brunke S, Brandt P, Loos D, Uribe R, de Oliveira Lino FS, Ni Y, Vylkova S, Slevogt H, Hube B, Weiss G, Sommer M, Panagiotou G# (2021) Metabolic modeling predicts specific gut bacteria as key determinants for Candida albicans colonization levels. ISME J 15(5), 1257-1270.
Ni Y*, Lohinai Z*, Heshiki Y, Dome B, Moldvay J, Dulka E, Galffy G, Berta J, Weiss GJ, Sommer MOA, Panagiotou G# (2021) Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients. ISME J 15(11), 3207-3220.